PhagoDAIR is a phase I/II clinical study for the treatment of osteoarticular infections of prostheses due to Staphylococcus aureus This Ethics... View Article
Author Archives for Adeline Chauvigné
Pherecydes Pharma receives a favorable opinion from the Ethics Committee to initiate the PhagoDAIR study
18 May 2024PhagoDAIR is a phase I/II clinical study for the treatment of osteoarticular infections of prostheses due to Staphylococcus aureus This Ethics... View Article
Valneva and Pfizer report further positive phase 2 data for Lyme disease vaccine candidate
Dose selection complete for planned Phase 3 trial, expected to be initiated in 3Q2022 Sub-analysis compared the immunogenicity of VLA15... View Article
Valneva and Pfizer report further positive phase 2 data for Lyme disease vaccine candidate
18 May 2024Dose selection complete for planned Phase 3 trial, expected to be initiated in 3Q2022 Sub-analysis compared the immunogenicity of VLA15... View Article
Transnational EU-project CE4BIG on Cluster Management Excellence and SME support draws to a close
In the framework of CE4BIG (Cluster Excellence for Business, Innovation and Growth in the health sector), supported bythe EU COSME... View Article
Transnational EU-project CE4BIG on Cluster Management Excellence and SME support draws to a close
18 May 2024In the framework of CE4BIG (Cluster Excellence for Business, Innovation and Growth in the health sector), supported bythe EU COSME... View Article
Valneva announces initiation of adolescent phase 3 trial for its single-shot chikungunya vaccine candidate
CEPI-funded trial intended to support potential label expansion in this age group Valneva, a specialty vaccine company, today announced the... View Article
Valneva announces initiation of adolescent phase 3 trial for its single-shot chikungunya vaccine candidate
18 May 2024CEPI-funded trial intended to support potential label expansion in this age group Valneva, a specialty vaccine company, today announced the... View Article
Ose Immunotherapeutics: license agreement with Veloxis Pharmaceuticals
OSE Immunotherapeutics Announced Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in... View Article
Ose Immunotherapeutics: license agreement with Veloxis Pharmaceuticals
18 May 2024OSE Immunotherapeutics Announced Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in... View Article
CUREETY, the French start-up specialized in data and remote-monitoring in oncology, raises €5 million
The financing round was led by French mutual insurance companies, with the support of Cureety’s existing investors, bank pool and... View Article
CUREETY, the French start-up specialized in data and remote-monitoring in oncology, raises €5 million
18 May 2024The financing round was led by French mutual insurance companies, with the support of Cureety’s existing investors, bank pool and... View Article
New member | GenSensor
By 2024, forecasts indicate that 50% of the top 100 most prescribed drugs will be biologics, accounting for 32% of... View Article
New member | GenSensor
18 May 2024By 2024, forecasts indicate that 50% of the top 100 most prescribed drugs will be biologics, accounting for 32% of... View Article
Valneva advances booster phase of Cov-Compare trial of its inactivated COVID-19 vaccine candidate
Valneva, a specialty vaccine company, today announced the start of booster vaccinations in adult participants from its Phase 3 pivotal... View Article
Valneva advances booster phase of Cov-Compare trial of its inactivated COVID-19 vaccine candidate
18 May 2024Valneva, a specialty vaccine company, today announced the start of booster vaccinations in adult participants from its Phase 3 pivotal... View Article
OSE Immunotherapeutics receives first notice of allowance of a patent for use of Tedopi®
OSE Immunotherapeutics receives first notice of allowance of a patent for use of Tedopi® after failure with PD-1 or PD-L1... View Article
OSE Immunotherapeutics receives first notice of allowance of a patent for use of Tedopi®
18 May 2024OSE Immunotherapeutics receives first notice of allowance of a patent for use of Tedopi® after failure with PD-1 or PD-L1... View Article
Valneva’s inactivated COVID-19 vaccine candidate shown to neutralize Omicron Variant
Preliminary laboratory studies demonstrate that three doses of Valneva’s inactivated COVID-19 vaccine candidate VLA2001 induced neutralization of the Omicron variant.... View Article
Valneva’s inactivated COVID-19 vaccine candidate shown to neutralize Omicron Variant
18 May 2024Preliminary laboratory studies demonstrate that three doses of Valneva’s inactivated COVID-19 vaccine candidate VLA2001 induced neutralization of the Omicron variant.... View Article